Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes. GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for…